BAGSVAERD, DENMARK--(Marketwire - February 09, 2009) - Novo Nordisk A/S has filed its Annual Report 2008 on Form 20-F for the financial year 2008 with the US Securities and Exchange Commission (SEC), incorporating by reference the Novo Nordisk A/S Annual Report 2008. The reports are available at the SEC's website, www.sec.gov as well as at: novonordisk.com - Investors - Download centre (listed under 2008).
Shareholders and ADR holders may receive a hard copy of the annual
reports free of charge upon request by filling out a request form at
novonordisk.com/investors/download-centre or upon request to either
tel no (609) 919 7937 or by e-mail to hrmm@novonordisk.com. When
e-mailing, please state the exact mailing address and the document(s)
you wish to receive.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Further information Media: Investors: Outside North America: Outside North America Mike Rulis Mads Veggerby Lausten Tel: (+45) 4442 3573 Tel: (+45) 4443 7919 mike@novonordisk.com mlau@novonordisk.com Kasper Roseeuw Poulsen Tel: (+45) 44424471 krop@novonordisk.com In North America: In North America Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 secl@novonordisk.com hrmm@novonordisk.com
Novo Nordisk files annual report with the SEC (http://hugin.info/2013/R/1288701/289923.pdf)
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
